	US 12,291,727 B2
	Method for producing stem cell-derived lacrimal gland tissue
Kohji Nishida, Osaka (JP); Ryuhei Hayashi, Osaka (JP); Toru Okubo, Osaka (JP); and Yoichi Honma, Osaka (JP)
Assigned to OSAKA UNIVERSITY, Osaka (JP)
Appl. No. 16/981,455
Filed by Osaka University, Osaka (JP)
PCT Filed Mar. 28, 2019, PCT No. PCT/JP2019/013759 § 371(c)(1), (2) Date Sep. 16, 2020, PCT Pub. No. WO2019/189640, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 2018-063077 (JP), filed on Mar. 28, 2018.
Prior Publication US 2021/0024896 A1, Jan. 28, 2021
Int. Cl. C12N 5/074 (2010.01); A61K 35/55 (2015.01)

CPC C12N 5/0696 (2013.01) [A61K 35/55 (2013.01); C12N 2501/11 (2013.01); C12N 2501/15 (2013.01); C12N 2513/00 (2013.01)]

6 Claims

1. A method for producing a stem cell-derived lacrimal gland tissue, the method comprising:

isolating SSEA4 and CD104 double positive cells from a self-formed ectodermal autonomous multi-zone (SEAM) cell population derived from pluripotent stem cells;

culturing the isolated SSEA4 and CD104 double positive cells to form spheroids, and

three-dimensionally culturing the spheroids in a medium comprising epidermal growth factor (EGF) and a ROCK inhibitor to produce a lacrimal gland tissue capable of expressing a lacrimal gland-related protein.